

1 ***A multi-centre cross-sectional study on hepatitis B***  
2 ***vaccination coverage and associated factors among***  
3 ***personnel working in health facilities in Kumasi,***  
4 ***Ghana***

5

6 **Daniel Kobina Okwan<sup>1</sup>, Godfred Yawson Scott<sup>2</sup>, Pius Takyi<sup>3</sup>, Clinton Owusu Boateng<sup>3</sup>,**  
7 **Philemon Boasiako Antwi<sup>3</sup>, Akwasi Amponsah Abrampah<sup>4</sup>, Michael Agyemang Obeng<sup>3\*</sup>**

8

9 **1** Department of Anatomy, Kwame Nkrumah University of Science and Technology, Kumasi,  
10 Ghana

11 **2** Department of Medical Diagnostics, Kwame Nkrumah University of Science and Technology,  
12 Kumasi, Ghana

13 **3** Kumasi Centre for Collaborative Research in Tropical Medicine, Kwame Nkrumah University  
14 of Science and Technology, Kumasi, Ghana

15 **4** Winneba Municipal Hospital, Ghana Health Service, Winneba, Ghana

16

17 Corresponding author: [\\*michaelagyemangobeng@gmail.com](mailto:*michaelagyemangobeng@gmail.com) (MAO)

18

19

20

## 21 **Abstract**

22 As part of efforts to reach the elimination target by 2030, the WHO and CDC recommend that all  
23 HCWs adhere to the 3-dose hepatitis B vaccination schedule to protect themselves against the  
24 infection. This study assessed Hepatitis B vaccination coverage and associated factors among  
25 personnel working in health facilities in Kumasi, Ghana.

26 A cross-sectional study involving 530 HCWs was conducted in four hospitals in Kumasi from  
27 September to November, 2023. An investigator-administered questionnaire was employed in  
28 gathering participant demographics and other information related to vaccination coverage. IBM  
29 SPSS version 26.0 and GraphPad prism 8.0 were used for analysing the data.

30 Even though, majority (70.6%) reported having taken at least one dose of the vaccine, only 43.6%  
31 were fully vaccinated ( $\geq 3$  doses). More than a quarter (29.4%) had not taken any dose of the HBV  
32 vaccine. Close to a quarter (23.6%) had not screened or tested for HBV infection in their lifetime.  
33 The Statistically significant variables influencing vaccination status were age, marital status,  
34 profession and status in the hospital. Majority (44.9%) of the participants who have not taken the  
35 vaccine reported they do not have reason for not taking the vaccine and high proportion (80.1%)  
36 were willing to take the vaccine when given for free.

37 To combat the low hepatitis B vaccination coverage among healthcare workers in Kumasi, Ghana,  
38 amidst the significant public health threat of HBV infection, comprehensive measures are  
39 necessary. These include implementing infection prevention control programmes, enhancing  
40 occupational health and safety, and conducting health promotion campaigns in healthcare  
41 facilities. Extending and intensifying hepatitis B screening and vaccination initiatives to tertiary  
42 institutions and encouraging employers, supervisors or team leaders to provide these services  
43 nationwide are also recommended.

## 44 **Introduction**

45 As a major risk to public health across the globe, chronic hepatitis B viral infection results in  
46 significant liver-related morbidity and mortality [1]. The hepatitis B virus (HBV) is a double-  
47 stranded DNA virus belonging to the Hepadnaviridae family [2]. An estimated 2 billion individuals  
48 worldwide apparently have been exposed to the HBV, and approximately 3 million of those cases  
49 have chronic infections that put them at risk of severe illness and even death [3,4]. Updated  
50 estimates from the World Health Organization (WHO) and the Global Burden of Disease research  
51 indicate that each year, viral hepatitis causes about 1.34 million fatalities [5]. Viral hepatitis has  
52 become the seventh biggest cause of death globally, with a 63% increase in mortality since 1990  
53 [6]. The increased rate of HBV infection and its fatalities made WHO adopt a global hepatitis  
54 strategy in May, 2016, to eliminate viral hepatitis as a public health threat by 2030 [7]. Currently,  
55 there is no cure for HBV infection; therefore, the only way to protect people all over the world is  
56 through the hepatitis B vaccination. The HBV vaccine was discovered in the year 1982. Since  
57 untreated HBV can cause cirrhosis and hepatocellular carcinoma, this vaccination was the first of  
58 its kind to prevent the cancer [8]. When administered according to the recommended schedule, the  
59 HBV vaccine provides 90–100% of healthy newborns, children, and adults with a protective  
60 concentration of anti-HBs ( $\geq 10$  mIU/mL) [9].

61 Africa has the largest proportion of HBV-positive people worldwide, making up 68% of the total  
62 burden [5]. Ghana, a country in Sub-Saharan Africa, has a significant public health issue with HBV  
63 illness that requires immediate attention [10]. The prevalence of chronic HBV infection in Ghana  
64 was 12.92%, according to a 2013 systematic review of data published between 1965 and 2013  
65 [11]. According to systematic review and meta-analysis published, the prevalence of HBV  
66 infection of in Ghana was as high as 12.3% in 2016 [12] and 8.36% in 2020 [10]. Ghana has

67 achieved progress in lowering HBV disease-related death and morbidity by introducing the  
68 pentavalent vaccine in 2002, which combines the hepatitis B, DPT, and Hib vaccines [13]. Even  
69 though the disease declined after the pentavalent vaccine was introduced, there are still issues with  
70 the vaccination that can be linked to a variety of circumstances, such as ignorance of and attitudes  
71 towards the vaccination. Adult vaccination cost has been implicated to be the cause, along with  
72 ignorance, deprivation, and resistance to change [14].

73 Numerous types of human contacts, including sexual and non-sexual kinds, needle-sharing and  
74 work- and health-related interactions, have been linked to HBV transmission [15]. As a result,  
75 those who work in specific occupations stand a higher chance of getting HBV infection than others.  
76 Healthcare workers (HCWs) are frequently exposed to bloodborne pathogens, which puts them at  
77 high risk of contracting HBV [14,16]. When providing care for patients who are HBV-positive,  
78 workplace exposure to the virus might happen from contaminated hospital surfaces or  
79 unintentional needlestick injuries (NSIs). According to WHO estimates, 2 million HCWs have  
80 needlestick injuries each year, and 3.3% of those individuals go on to acquire hepatitis B after  
81 suffering sharp injury [17]. Therefore, WHO and Centre for Disease Control and Prevention  
82 (CDC) recommend that HCWs get the hepatitis B vaccination as a routine preventative measure  
83 [7,18]. HCWs are the ones who will help educate and encourage the hepatitis B vaccination among  
84 the general public, thus their understanding of the virus, the infection sequelae, and the need for  
85 vaccination is very crucial in controlling the HBV infection. A study conducted by Demsiss et al.  
86 [19] indicated a high seroprevalence but poor practice of hepatitis B and C virus infection among  
87 medicine and health science students despite their good knowledge of the occupational risk of viral  
88 hepatitis infection. These students are supposed to follow good practices for hepatitis B virus

89 infection since they will be taking over the health system as practitioners in the near future soon  
90 to come.

91 A study conducted among HCWs in Bantama, Ghana, highlighted unsatisfactory or poor  
92 knowledge, attitude, and practice toward the hepatitis B virus and some important aspects of viral  
93 hepatitis [15]. Another study conducted by Obeng et al. [20] found the prevalence of hepatitis B  
94 viral (HBV) infection among vaccinated HCWs to be 2.4%. This study highlights the need for all  
95 HCWs not only to complete their hepatitis B vaccination but also to do the post-vaccination  
96 serological testing to confirm immunity [20]. The study proved that HCWs who have not taken  
97 the hepatitis B vaccine stand a very high risk of contracting the infection. There is not much data  
98 on hepatitis B vaccination coverage among HCWs in the country. As Ghana is highly endemic to  
99 HBV infection, this data will be needed to ascertain if the existing control programmes are  
100 effective in achieving national targets as set by WHO for 2030 HBV elimination [7]. Therefore,  
101 this study aimed at determining the vaccination coverage and throw more light on factors  
102 influencing the vaccination uptake among personnel working in select health facilities in Kumasi,  
103 Ghana.

104

105

106

107

108

109

110

111

## 112 **Materials and Methods**

### 113 **Study Design and population**

114 A cross-sectional study was conducted in four hospitals in Kumasi from 5<sup>th</sup> September to 9<sup>th</sup>  
115 November, 2023. These study sites included Ashanti Regional Hospital, Suntreso Government  
116 Hospital, Maternal and Child Health Hospital and Manhyia District Hospital.

117 Kumasi, the second largest city in Ghana, is situated between latitudes 6.35°N and 6.40°N and  
118 longitudes 1.3°W and 1.35°W. Covering an area of approximately 150 square kilometres, it resides  
119 within the rainforest region of West Africa. The city has a population of around 2 million  
120 inhabitants [21].

121 In the suburbs of Kumasi [22], reported the prevalence levels of HBsAg to be 6.78% in Garrison,  
122 9.02% in Aboabo, and 10.0% in Tafo. The overall prevalence of HBsAg sero-positivity within the  
123 study population was calculated to be 8.68%. These findings indicate that local prevalence rates  
124 of HBsAg can vary significantly within different areas of Kumasi.

125 A total of 530 participants were recruited using a purposive sampling technique from the four  
126 different health facilities. The sample size was calculated using the *Raosoft* sample size calculator  
127 [23]. The minimum sample size required for this study was 377 participants at 95% confidence  
128 level, 5% margin of error, and a response distribution of 50%. It was increased to 530 in order to  
129 increase the statistical power of prediction.

### 130 **Ethical consideration**

131 Ethical approval was sought from the Committee on Human Research, Publication and Ethics  
132 (CHRPE), School of Medical Sciences, Kwame Nkrumah University of Science and Technology  
133 (KNUST) (Reference number: CHRPE/AP/331/23). Approval letters were obtained from all four

134 study sites before the commencement of the study. All participants gave their written informed  
135 consent after the aim and procedure of the study had been explained to them.

136

## 137 **Inclusion and exclusion criteria**

138 The study participants were HCWs comprising clinicians, pharmacists, laboratory scientists,  
139 nurses, midwives, administrative staff, securities and cleaners. Healthcare workers in the four  
140 study sites during the study period who were willing to participate in the study were included.  
141 Healthcare workers on fieldwork, maternity, annual, or sick leave who were unable to remain in  
142 the study area during the data-collecting period were excluded.

143

## 144 **Data Collection**

145 A well-structured questionnaire was validated and administered to the participants within the  
146 framework of the study variables consisting of participant demographics and other information  
147 related to vaccination coverage. The data were collected using an investigator-administered  
148 questionnaire in a language that they could easily comprehend (English and Twi).

149 We engaged in pilot interviews and discussions with a cohort of healthcare workers to enhance the  
150 clarity and applicability of our research questionnaire. Their feedback enabled us to fine-tune the  
151 questionnaire, ensuring it was more accessible to patients and effectively captured pertinent  
152 information. Before commencing data collection, all researchers involved underwent training. At  
153 the conclusion of each day's data gathering, a team of investigators meticulously reviewed the  
154 obtained data for inconsistencies and omissions. Subsequently, data cleaning procedures were  
155 implemented to ensure accuracy, consistency, and completeness of variables. Any incomplete  
156 participant responses were identified, rejected, and excluded from the dataset before analysis.

157

158

## 159 **Definition of key concepts**

160 **HBV vaccination schedule** is the hepatitis B vaccine injection that is generally given  
161 intramuscularly in the arm (deltoid muscle) as a three-dose series on a 0,1, and 6-month schedule.

162 **Health care workers** in this study, include all those who work in the hospital settings were  
163 considered as healthcare workers (HCWs). They included clinicians, nursing and midwifery staff  
164 members, laboratory staff members, laboratory students, administration staff members,  
165 pharmacists, cleaners and security personnel.

166 **Complete HBV vaccination** refers to a participant who has taken 3 or more doses of the hepatitis  
167 B vaccine.

168 **Incomplete HBV vaccination** in the study, referred to all who had received only one dose or two  
169 doses of the HBV vaccine.

170 **Vaccination status** refers to whether or not a participant has taken any dose of the hepatitis B  
171 vaccine. Participants who have taken at least one dose of the vaccine represent “Yes” and those  
172 who have not taken any dose represent “No” vaccination status.

173

## 174 **Data analysis**

175 Data entry was done using Microsoft Excel 2019 and analysis was performed using IBM SPSS  
176 Version 26.0 and GraphPad Prism version 8.0. Categorical data were presented as frequency  
177 (proportion). Multivariate logistic regression analysis was performed to evaluate the factors that

178 influence vaccination coverage of the study participants. All statistical results obtained were  
179 considered at a significant value of  $p < 0.05$ .

180

181

182

183

184

185

186

187

188

189

190

## 191 **Results**

### 192 **Hepatitis B vaccination status**

193 Majority (70.6%) of the study participants had taken at least one dose of the Hepatitis B vaccine.

194 Among those who had taken the vaccine, 43.6% were fully vaccinated ( $\geq 3$  doses) while (27.0%)  
195 had taken one or two doses of the vaccine. Meanwhile, 29.4% indicated that they had not taken  
196 any dose of the hepatitis B vaccine (**Fig 1**).

#### 197 **Fig 1: Hepatitis B vaccination status**

198

199

200

201

202

### 203 **Association between sociodemographic characteristics and** 204 **vaccination status**

205 Majority (66.2%) of the participants were aged 20-30 years. Most (72.6%) of them were females and were  
206 single (72.5%). Most of them were from the Ashanti region (66.6%) and were Christians (91.1%). Most of  
207 them were Diploma holders (56.6%) and were clinical staff members (83.4%) at the respective hospitals.  
208 Majority of them were contract staff members (66.2%) and were mainly from the Manhyia Government  
209 Hospital (39.4%). Individually, age group, marital status, status in hospital and profession were  
210 significantly associated with vaccination status of the participants ( $p < 0.001$ ) (**Table 1.0**)

211

212

213

214 **Table 1: Association between sociodemographic characteristics and vaccination status**

Variable	Frequency (n=530)	Percentage (%)	Vaccination Status		p-value
			Yes (n=374)	No (n=156)	
<b>Age Group (In Years)</b>					<b>&lt;0.001</b>
<20	29	5.5	14(48.3)	15(51.7)	
20-30	351	66.2	236(67.2)	115(32.8)	
31-40	115	21.7	100(87.0)	15(13.0)	
>40	35	6.6	21(68.6)	11(31.4)	
<b>Sex</b>					0.075
Male	145	27.4	94(64.8)	51(35.2)	
Female	385	72.6	280(72.7)	105(27.3)	
<b>Marital Status</b>					<b>&lt;0.001</b>
Single	384	72.5	252(65.6)	132(34.4)	
Married	144	27.2	121(84.0)	23(16.0)	
Divorced	2	0.4	1(50.0)	1(50.0)	
<b>Region</b>					0.408
Ashanti	353	66.6	245(69.4)	108(30.6)	
Others	117	33.4	129(72.9)	48(27.1)	
<b>Religion</b>					0.468
Christianity	483	91.1	343(71.0)	140(29.0)	
Islam	47	8.9	31(66.0)	16(34.0)	
<b>Educational Level</b>					0.216
Certificate and less	36	6.8	21(58.3)	15(41.7)	
Diploma	300	56.6	217(72.3)	83(27.7)	
First Degree and Higher	194	36.6	136(70.1)	58(29.9)	
<b>Profession</b>					<b>0.001</b>
Lab Scientist	46	8.7	37(80.4)	9(19.6)	
Clinician	31	5.8	22(71.0)	9(29.0)	
Nurse/Midwife	358	67.5	264(73.7)	94(26.3)	
Pharmacist	19	3.6	13(68.4)	6(31.6)	
Others	76	14.3	38(50.0)	38(50.0)	
<b>Status In Hospital</b>					<b>&lt;0.001</b>
Permanent Staff	179	33.8	233(79.3)	61(20.7)	
Non-Permanent Staff	351	66.2	141(59.7)	95(40.3)	
<b>Name of Health Facility</b>					0.692
Kumasi South Hospital	123	23.2	84(68.3)	39(31.7)	
M.C.H Hospital	60	11.3	46(76.7)	14(23.3)	
Manhyia Government Hospital	185	39.4	129(69.7)	56(30.3)	
Suntreso Government Hospital	162	30.6	115(71.0)	47(29.0)	

215 Data is presented as frequency (%); Chi square/ Fisher's Exact, p-value <0.05 was considered statistically significant  
 216 for vaccination status. The bold values indicate p-values which are statistically significant

217

218

## 219 **Association between knowledge on Hepatitis B and vaccination and** 220 **vaccination status**

221 Most (76.4%) of the participants had done the Hepatitis B test at least once in their life time, while (23.6%)  
222 had not done Hepatitis B test before. Majority (44.9) of those who had done the test reported they wanted  
223 to know their Hepatitis B status as reason for testing. Most (49.6%) of those who had not done the Hepatitis  
224 B test indicated that they did not have any reason for not testing. Also, majority (44.9%) of those who had  
225 not been vaccinated indicated that they did not have any reason for not vaccinating. Most (80.1%) of those  
226 who had not taken the vaccine were willing to take the vaccine when given to them free of charge. About  
227 (61.8%) of those who had been vaccinated had taken  $\geq 3$  doses and self-initiative (43.9%) was their source  
228 of Hepatitis B vaccination. Most (30.4%) of them indicated that the cost for Hepatitis B vaccination and  
229 testing was reasonable. Having done the Hepatitis B test before, reason for doing the test, number of  
230 Hepatitis B vaccine doses taken if vaccinated, source of hepatitis B vaccination if vaccinated, how  
231 expensive is Hepatitis B testing and vaccination, willingness to take Hepatitis B vaccine if given for free  
232 were all significantly associated with vaccination status ( $p < 0.001$ ) (**Table 2.0**).

233

234

235

236

237

238

239

240

241

242 **Table 2: Association between knowledge on Hepatitis B and vaccination status**

Variable	Frequency	Percentage (%)	Vaccination Status		p-value
			Yes (n=374)	No (n=156)	
<b>Have you done Hepatitis B test Before</b>					<b>&lt;0.001</b>
Yes	405	76.4	355(87.7)	19(15.2)	
No	125	23.6	50(12.3)	106(84.8)	
<b>If yes, what was your reason for testing</b>	<b>(n=405)</b>				<b>&lt;0.001</b>
Just wanted to know my hepatitis B status (Self initiative)	182	44.9	156(85.7)	26(14.3)	
It was an institutional requirement	125	30.9	108(86.4)	17(13.6)	
Testing in order to take the vaccine	64	15.8	63(98.4)	1(1.6)	
Other	34	8.4	28(82.4)	6(17.6)	
<b>If no, what was your reason for not testing for hepatitis B?</b>	<b>(n=125)</b>				<b>&lt;0.001</b>
Do not have any reason	62	49.6	1(3.4)	51(82.3)	
Do not get time	29	23.2	11(17.7)	28(96.6)	
Other	34	27.2	7(20.6)	27(79.4)	
<b>If no, what was your reason for not getting vaccinated (n=156)</b>					<b>&lt;0.001</b>
Do not have any reason	70	44.9	0(0.0)	70(100.0)	
Busy schedule	32	20.5	0(0.0)	32(100.0)	
Other	54	34.6	0(0.0)	54(100.0)	
<b>If no, (not vaccinated), will you take the hepatitis B vaccine if it were given free of charge?</b>	<b>(n=156)</b>				<b>&lt;0.001</b>
Yes	125	80.1	0(0.0)	125(100.0)	
No	31	19.9	0(0.0)	31(100.0)	
<b>If yes (vaccinated), how many doses of the hepatitis B vaccine have you taken?</b>	<b>(n=374)</b>				<b>&lt;0.001</b>
1	48	12.8	48(100.0)	0(0.0)	
2	95	25.4	95(100.0)	0(0.0)	
≥3	231	61.8	231(100.0)	0(0.0)	

<b>If yes (vaccinated), what was your source of hepatitis B vaccination?</b>				<b>&lt;0.001</b>
	<b>(n=374)</b>			
Organized by school	136	36.4	136(100.0)	0(0.0)
By self-initiative	164	43.9	164(100.0)	0(0.0)
Organized by my hospital	30	8	30(100.0)	0(0.0)
Other	44	11.8	44(100.0)	0(0.0)
<b>How expensive do you think is the testing and vaccination of Hepatitis B?</b>				<b>&lt;0.001</b>
Cheap	139	26.2	111(79.9)	28(20.1)
Reasonable	161	30.4	139(86.3)	22(13.7)
Expensive	69	13	48(69.6)	21(30.4)
Don't know	135	25.5	57(42.2)	78(57.8)
Others	26	4.9	19(73.1)	7(26.9)

243 Data is presented as frequency (%); Chi square/ Fisher's Exact, p-value <0.05 was considered statistically significant

244 for vaccination status. The bold values indicate p-values which are statistically significant

245

246 **Univariate and multivariate logistic regression model of**  
 247 **sociodemographic, knowledge on Hepatitis B and vaccination and**  
 248 **predictors of vaccination status among study participants**

249 In a univariate logistic regression model, age group, status in hospital, profession, whether or not

250 one has done the Hepatitis B test before, reason for doing or not doing the Hepatitis B test,

251 expensive nature of Hepatitis B testing and vaccination were predictors of vaccination status.

252 After adjusting for age in the multivariate logistic regression model, have not done hepatitis B test

253 before [aOR= 170.937. 95% CI (19.003-1537.625), p < 0.001], institutional requirement as the

254 reason for testing [aOR= 9.277. 95% CI (1.174-73.323), p=0.035], just wanted to know my hepatitis

255 B status (Self initiative) as the reason for testing [aOR= 8.785. 95% CI (1.143-67.556), p=0.037],

256 other as the reason for testing [ aOR= 15.479. 95% CI (1.715-139.670), p=0.015], and don't know

257 how expensive Hepatitis B testing and Vaccination is [aOR= 2.993. 95% CI (1.392-6.435), p=0.005]

258 were the independent predictors of Hepatitis B vaccination status (**Table 3.0**).

259

260

261

262

263

264

265

266

267

268

269

270

271

272

273

274

275

276 **Table 3: Univariate and multivariate logistic regression model of sociodemographic, knowledge on**  
 277 **Hepatitis B and vaccination and predictors of vaccination status among study participants**

Variable	cOR (95% CI)	p-value	aOR (95% CI)	p-value
<b>Age Group (In Years)</b>				
<20	0.428(0.154-1.186)	0.103	1.184(0.191-7.324)	0.856
20-30	0.941(0.445-1.987)	0.872	0.605(0.152-2.415)	0.477
31-40	3.056(1.247-7.490)	<b>0.015</b>	0.687(0.213-2.221)	0.531
>40	1.00			
<b>Marital Status</b>				
Single	1.00			
Married	5.261(0.318-87.159)	0.246	-	-
Divorced	1.909(0.118-30.766)	0.648	-	-
<b>Profession</b>				
Clinician	0.595(0.205-1.723)	0.338	0.882(0.209-3.711)	0.864
Nurse/Midwife	0.683(0.318-1.469)	0.329	0.516(0.183-1.454)	0.211
Others	0.243(0.104-0.573)	<b>0.001</b>	2.333(0.760-7.158)	0.139
Pharmacist	0.527(0.157-1.769)	0.3	0.624(0.118-3.283)	0.557
Lab Scientist	1.00			
<b>Status In Hospital</b>				
Non-Permanent Staff	1.00			
Permanent Staff	2.574(1.754-3.777)	<b>&lt;0.001</b>	0.694(0.356-1.353)	0.283
<b>Have you done Hepatitis B test Before</b>				
Yes	1.00			
No	39.611(22.378-70.114)	<b>&lt;0.001</b>	170.937(19.003-1537.625)	<b>&lt;0.001</b>
<b>If yes, what was your reason for testing</b>				
It was an institutional requirement	0.101(0.013-0.776)	<b>0.028</b>	9.277(1.174-73.323)	<b>0.035</b>

Just wanted to know my hepatitis B status (Self initiative)	0.095(0.013-0.717)	<b>0.022</b>	8.785(1.143-67.556)	<b>0.037</b>
Other	0.074(0.009-0.644)	<b>0.018</b>	15.479(1.715-139.670)	<b>0.015</b>
Testing in order to take the vaccine	1.00			
<b>If no, what was your reason for not testing for hepatitis B?</b>				
Do not have any reason	198.8(26.464-1493.395)	<b>&lt;0.001</b>	0.959(0.313-2.939)	0.942
Do not get time	6.039(0.741-49.237)	<b>0.093</b>	8.912(0.989-80.315)	0.051
Other	1.00			
<b>How expensive do you think is the testing and vaccination of Hepatitis B?</b>				
Cheap	0.627(0.340-1.157)	0.135	1.160(0.535-2.518)	0.707
Don't know	0.116(0.066-0.203)	<b>&lt;0.001</b>	2.993(1.392-6.435)	<b>0.005</b>
Expensive	0.362(0.183-0.716)	<b>0.003</b>	1.408(0.558-3.555)	0.469
Others	0.430(0.162-1.140)	0.09	1.935(0.497-7.534)	0.341
Reasonable	1.00			

278 cOR, Crude Odd ratio; aOR, Adjusted Odd ratio; CI, Confidence interval; 1.00, reference. Binary logistic regression

279 analysis performed to obtain odd ratios. p-value of < 0.05 was considered statistically significant. The bold values

280 indicate p-values which are statistically significant

281

282

283

284

285

286

## 287 Discussion

288 Ghana is one of the countries in Africa classified as being highly endemic to HBV infection [24].

289 The national HBV prevalence is higher than 8%, which means that everyone living in Ghana is at  
290 a high risk of contracting HBV infection [10,12]. As a results of the nature of their work, HCWs  
291 in this country even have a higher risk of contraction HBV infection compared to the general  
292 Ghanaian population. This makes it relevant for all HCWs in Ghana to adhere to the complete  
293 HBV vaccination schedule [25-28].

294 Even though 70.6% of study participants self-reported having taken at least one dose of the  
295 hepatitis B vaccine ( $\geq 1$  dose) with 29.4% having taken no dose of the vaccine at all, the overall  
296 complete vaccination coverage ( $\geq 3$  doses) was low (43.6%). This seemingly low complete  
297 vaccination coverage (43.6%) is comparable to similar studies (42.3%, 46.8%) in HCWs in other  
298 regions of Ghana [29, 30]. It is also consistent with findings from another study by Issa et al. [31]  
299 (42.0%) in Nigeria. This vaccination coverage is far lower than what is expected of a high-risk  
300 group like HWCs per the recommendation by WHO and Centre for Disease Control and  
301 Prevention (CDC) [18, 32]. Still, finding from this current study is higher than what was observed  
302 by other studies in Africa. For instance, complete vaccination coverage ( $\geq 3$  doses) was reported  
303 by Biset AM & Adugna HB, 2017 to be 28.7% in Ethiopia [33], 24.5% in Cameroon by Noubiap  
304 *et al.*, 2014 [34], 16.4% in Somalia by Hussein *et al.* [35], 12.9% in Ethiopia by Abebaw et al. [36]  
305 and 10.9% in Burkina Faso by Ouédraogo *et al.* [37]. This brings to the fore, the generally low  
306 vaccination coverage in Ghana and African at large [38,39]. The observed complete vaccination  
307 coverage in this study is lower compared to what has been found in a study by Yuan *et al.* (60%)  
308 in China [40] and Guthmann *et al.* (91.7%) in France [41].

309 The study found that 76.4% of participants had undergone Hepatitis B testing at least once in their  
310 lifetime. Since the hepatitis B testing is prerequisite for the vaccination, it is suggestive of potential  
311 likelihood of vaccination compliance and the high awareness of the risk of HBV infection on the  
312 part of the participants. Significant associations were found between demographic factors such as  
313 age, marital status, professional status and vaccination status. Specifically, in the present study,  
314 participants aged 31-40 years had the highest ( $\geq 1$  dose) vaccination rate (87.0%), with the least  
315 among those aged below 20 years (48.3%). This is not surprising as literature supports the notion  
316 that individuals older than 20 years may have higher vaccination rates due to longer exposure to  
317 healthcare settings and potentially greater awareness of the importance of vaccination [16]. Also,  
318 congruent with findings of this research, a study conducted in Ghana among university students  
319 had majority of the vaccinees to be 26 years and above [42]. Meanwhile, previous research has  
320 also shown that younger age groups tend to have higher vaccination rates, possibly due to increased  
321 awareness and education [19]. This is relative as the younger could be in line with the 31-40 years  
322 age group.

323 The major motivating factor for testing was to know their Hepatitis B infection status. This is in  
324 line with existing literature, emphasizing the importance of individuals' motivation to know their  
325 health status, particularly regarding infectious diseases like Hepatitis B [17]. Self-initiative being  
326 the commonest impulse of Hepatitis B vaccination is suggestive that proactive behaviour among  
327 healthcare workers plays a crucial role in ensuring vaccination uptake [14]. According to a related  
328 study, the common reasons given for not getting vaccinated were the non-obligatory nature of the  
329 Hepatitis B vaccination, lack of knowledge about the shot, its expensive cost, lack of interest or  
330 desire and problems with availability [16, 29].

331 While the association between sex and vaccination status was not statistically significant, there  
332 was a significant association between marital status and vaccination status ( $p < 0.001$ ). Married  
333 individuals had a higher vaccination rate compared to single individuals. These findings suggest  
334 that marital status may influence vaccination behaviour, possibly due to shared healthcare  
335 decisions among married couples [14]. This could also be attributed to the pre-marital laboratory  
336 screening testing for would-be couples. A study carried out among Nigerians; higher rate of  
337 hepatitis B vaccinations were observed among married couples [43]. This underscores the  
338 importance of tailored vaccination strategies targeting different age groups and marital statuses.  
339 The associations between region, religion, and educational level with vaccination status were not  
340 statistically significant. While these factors did not show significant associations in this study,  
341 variations in vaccination uptake across regions, religious beliefs, and educational levels have been  
342 reported in other settings and therefore warrant further investigation [10].

343 Regardless of health facility, there was a significant association between profession and status in  
344 the hospital with vaccination status [35, 44]. These findings highlight the influence of occupational  
345 factors and employment status on vaccination behaviour among healthcare workers, with clinical  
346 staff members and permanent employees showing higher vaccination rates [14]. This is possible  
347 due to the fact that, clinical and permanent staff members are often taken through routine health  
348 assessments prior to their posting to their working stations. According to a Ghanaian study  
349 consistent with the proposition of the current study findings, working for more than 16 years, doing  
350 invasive procedures routinely, being around blood-stained linens and garbage, and being exposed  
351 to blood and or its products on a daily basis were all linked to higher hepatitis B vaccination rates  
352 [29].

353 The finding that participants who had undergone Hepatitis B testing had significantly higher  
354 vaccination rates aligns with previous research where individuals who are aware of their Hepatitis  
355 B status are more likely to seek vaccination if they are unvaccinated [16]. In a study involving 114  
356 undergraduate students studying public health in Ghana, about half (50.4%) had never had their  
357 HBV infection checked, and 100 (44.2%) had at least one dose of the vaccine [45]. This implies  
358 that, the greater the number of individuals participating in pre-vaccination hepatitis B screening  
359 exercise, the greater the fraction of potential coverage of the vaccination. The present study  
360 recording the primary reason for testing being self-initiative reflects a proactive approach toward  
361 health awareness among the study participants. This is consistent with findings from studies  
362 emphasizing the importance of individual motivation and health-seeking behaviour in infectious  
363 disease prevention [14,46]. Relatively high number participants (43.9%) reported to have taken  
364 the vaccine as a result of their own initiative and good proportion (36.4%) also reported having  
365 been given the vaccine by their schools. Only a small proportion (8%) reported having taken the  
366 vaccine as a result of vaccination exercise organized by their workplace (hospitals). This area  
367 needs attention since schools and workplaces arranging for hepatitis B vaccinations for its students  
368 and workers respectively could increase vaccination coverage in Ghana. In this current study, most  
369 (80.1%) of the unvaccinated respondents were ready to take the vaccine if given at no cost. Efforts  
370 to reduce or eliminate costs associated with testing and vaccination could potentially improve  
371 vaccination coverage among healthcare workers.

372 Interestingly, among those who had not received any dose of the vaccine, a significant proportion  
373 (44.9%) mentioned that they did not have any reason for not getting vaccinated. This suggests that  
374 occupational health and safety programmes, infection prevention and control programmes,  
375 together with health promotion campaigns in the various health facilities could reiterate the need

376 for vaccination adherence and subsequent improved vaccination coverage. The current study also  
377 found that, only 13% of the participants reported that the cost of HBV vaccination in the country  
378 is expensive, while 82.1% of the participants reported that the cost was cheap, expensive or do not  
379 know. This suggests also that, the cost of test and vaccination may not be a key reason for low  
380 vaccination coverage among this study population. Perhaps increasing awareness and  
381 establishment of vaccination policies in health institutions could increase vaccination coverage.

382 Interestingly, there was a statistically significant differences among professions as far as the  
383 vaccination status ( $\geq 1$  dose) is concerned. While laboratory scientists recorded the highest  
384 vaccination coverage (80.4%), followed by Nurses/Midwives (73.7%), Clinicians (71.0%), then  
385 pharmacists (68.4%), participants from other professions (such as cleaners, administrative staff,  
386 etc) recorded the least vaccination coverage (50.0). Meanwhile, a systematic review on HBV  
387 vaccination coverage in Africa found clinicians to be having the highest vaccination coverage [38].

### 388 **Limitations and strengths of the study**

389 One of the limitations of this study is the possible recall bias on the part of the participants since  
390 vaccination status was self-reported and not verified from properly documented sources.  
391 Meanwhile, unlike childhood vaccination which could be more difficult to recall, HCWs are less  
392 likely to forget vaccination in their adulthood.

393 This study has several strengths, it has brought to the fore, the current HBV vaccination status of  
394 HCWs in Kumasi. Also, it has been able to identify several factors associated with HBV  
395 vaccination coverage among HCWs. Furthermore, this study was a multi-centre research making  
396 the findings more generalizable, unlike other studies done in the country which involved only one  
397 study centre. Again, all cadres of HCWs together with non-medical hospital staff members were  
398 included in this study irrespective of the duration of employment or nature of work. In this way,

399 the findings from the current study give a better representation of all HWCs in the facilities  
400 selected.

## 401 **Conclusion**

402 The hepatitis B vaccination coverage among HCWs as well as other hospital staff members in  
403 Kumasi is low. The HBV infection poses a significant public health challenge in a country like  
404 Ghana which has been classified as endemic to HBV infection. We therefore propose  
405 implementing programmes for infection prevention and control, occupational health and safety,  
406 and health promotion campaigns across the healthcare facilities in Ghana to improve vaccination  
407 coverage. Additionally, we recommend conducting hepatitis B screening and vaccination  
408 initiatives in all tertiary academic institutions, and employers in Ghana should arrange these  
409 services for their employees including the temporary and non-medical staff members.

410

## 411 **Acknowledgements**

412 We are much grateful to the management of all the hospitals involved in this study. We also express  
413 our appreciation to all individuals who willingly participated in the study.

414

415

416

417

418

## 419 **References**

- 420 1. Seto WK, Lo YR, Pawlotsky JM, Yuen MF. Chronic hepatitis B virus infection. The  
421 Lancet. 2018 Nov 24;392(10161):2313-24
- 422 2. Liaw YF, Chu CM. Hepatitis B virus infection. The lancet. 2009 Feb 14;373(9663):582-  
423 92.
- 424 3. Ott JJ, Stevens GA, Groeger J, Wiersma ST. Global epidemiology of hepatitis B virus  
425 infection: new estimates of age-specific HBsAg seroprevalence and endemicity. Vaccine.  
426 2012 Mar 9;30(12):2212-9.
- 427 4. Jefferies M, Rauff B, Rashid H, Lam T, Rafiq S. Update on global epidemiology of viral  
428 hepatitis and preventive strategies. World journal of clinical cases. 2018 Nov 11;6(13):589.
- 429 5. World Health Organization. Global hepatitis report 2017. World Health Organization;  
430 2017.
- 431 6. Stanaway JD, Flaxman AD, Naghavi M, Fitzmaurice C, Vos T, Abubakar I, Abu-Raddad  
432 LJ, Assadi R, Bhala N, Cowie B, Forouzanfour MH. The global burden of viral hepatitis  
433 from 1990 to 2013: findings from the Global Burden of Disease Study 2013. The Lancet.  
434 2016 Sep 10;388(10049):1081-8.
- 435 7. World Health Organization. Global health sector strategy on viral hepatitis 2016-2021.  
436 Towards ending viral hepatitis. World Health Organization; 2016.
- 437 8. Razavi-Shearer D, Gamkrelidze I, Nguyen MH, Chen DS, Van Damme P, Abbas Z,  
438 Abdulla M, Abou Rached A, Adda D, Aho I, Akarca U. Global prevalence, treatment, and  
439 prevention of hepatitis B virus infection in 2016: a modelling study. The lancet  
440 Gastroenterology & hepatology. 2018 Jun 1;3(6):383-403.
- 441 9. Shepard CW, Simard EP, Finelli L, Fiore AE, Bell BP. Hepatitis B virus infection:  
442 epidemiology and vaccination. Epidemiologic reviews. 2006 Aug 1;28(1):112-25.

- 443 10. Abesig J, Chen Y, Wang H, Sompo FM, Wu IX. Prevalence of viral hepatitis B in Ghana  
444 between 2015 and 2019: A systematic review and meta-analysis. *PloS one*. 2020 Jun  
445 12;15(6):e0234348.
- 446 11. Schweitzer A, Horn J, Mikolajczyk RT, Krause G, Ott JJ. Estimations of worldwide  
447 prevalence of chronic hepatitis B virus infection: a systematic review of data published  
448 between 1965 and 2013. *The Lancet*. 2015 Oct 17;386(10003):1546-55.
- 449 12. Ofori-Asenso R, Agyeman AA. Hepatitis B in Ghana: a systematic review & meta-analysis  
450 of prevalence studies (1995-2015). *BMC infectious diseases*. 2016 Dec;16(1):1-5.
- 451 13. Dodoo AN, Renner L, van Grootheest AC, Labadie J, Antwi-Agyei KO, Hayibor S,  
452 Addison J, Pappoe V, Appiah-Danquah A. Safety monitoring of a new pentavalent vaccine  
453 in the expanded programme on immunisation in Ghana. *Drug safety*. 2007 Apr;30:347-56.
- 454 14. Afihene MY, Duduyemi BM. Knowledge, attitude and practices concerning Hepatitis B  
455 infection, among healthcare workers in Bantama, Ghana: a cross sectional study.
- 456 15. Shepard CW, Simard EP, Finelli L, Fiore AE, Bell BP. Hepatitis B virus infection:  
457 epidemiology and vaccination. *Epidemiologic reviews*. 2006 Aug 1;28(1):112-25.
- 458 16. Harun MG, Sumon SA, Mohona TM, Rahman A, Abdullah SA, Islam MS, Anwar MM.  
459 Hepatitis B Vaccination Coverage among Bangladeshi Healthcare Workers: Findings from  
460 Tertiary Care Hospitals. *Vaccines*. 2022 Dec 24;11(1):41.
- 461 17. Prüss-Üstün A, Rapiti E, Hutin Y. Estimation of the global burden of disease attributable  
462 to contaminated sharps injuries among health-care workers. *American journal of industrial  
463 medicine*. 2005 Dec;48(6):482-90.

- 464 18. Conners EE, Panagiotakopoulos L, Hofmeister MG, Spradling PR, Hagan LM, Harris AM,  
465 et al. Screening and Testing for Hepatitis B Virus Infection: CDC Recommendations —  
466 United States, 2023. *MMWR Recomm Rep.* 2023 Mar 10;72(1):1–25.
- 467 19. Demsiss W, Seid A, Fiseha T. Hepatitis B and C: Seroprevalence, knowledge, practice and  
468 associated factors among medicine and health science students in Northeast Ethiopia. *PLoS*  
469 *One.* 2018 May 15;13(5):e0196539.
- 470 20. Obeng MA, Okwan DK, Adankwah E, Owusu PK, Gyamerah SA, Duah KB, Paintsil EK.  
471 Seroconversion and prevalence of Hepatitis B surface antigen among vaccinated health  
472 care workers in Ashanti Region, Ghana. *Advances in Medicine.* 2023 Dec 19;2023.
- 473 21. Gss GSS, NMIMR/Ghana NMI for MR, Macro ORC. Ghana Demographic and Health  
474 Survey 2003. 2004 Sep 1 [cited 2024 Apr 21]; Available from:  
475 <https://dhsprogram.com/publications/publication-FR152-DHS-Final-Reports.cfm>
- 476 22. Amidu N, Alhassan A, Obirikorang C, Feglo P, Majeed SF, Timmy E, et al. Sero-  
477 prevalence of hepatitis B surface (HBsAg) antigen in three densely populated communities  
478 in Kumasi, Ghana.
- 479 23. Sample Size Calculator by Raosoft, Inc. [Internet]. [cited 2024 Apr 21]. Available from:  
480 <http://www.raosoft.com/samplesize.html>
- 481 24. Schweitzer A, Horn J, Mikolajczyk RT, Krause G, Ott JJ. Estimations of worldwide  
482 prevalence of chronic hepatitis B virus infection: a systematic review of data published  
483 between 1965 and 2013. *The Lancet.* 2015 Oct;386(10003):1546–55
- 484 25. Roy Biswas R, Karim M, Bhattacharjee B. Hepatitis B virus infection and vaccination  
485 status among health care workers of a tertiary care hospital in Bangladesh. *J Sci Soc.*  
486 2015;42: 176. doi:10.4103/0974-5009.165561

- 487 26. Beltrami EM, Williams IT, Shapiro CN, Chamberland ME. Risk and Management of  
488 Blood-Borne Infections in Health Care Workers. *Clin Microbiol Rev.* 2000;13: 385–407.  
489 doi:10.1128/CMR.13.3.385-407.2000
- 490 27. SHAPIRO CN, TOKARS JI, CHAMBERLAND ME. Use of the Hepatitis-B Vaccine and  
491 Infection with Hepatitis B and C among Orthopaedic Surgeons\*. *J Bone Jt Surg.* 1996;78:  
492 1791–1800. doi:10.2106/00004623-199612000-00001
- 493 28. Ganczak M, Ostrowski M, Szych Z, Korzeń M. A complete HBV vaccination coverage  
494 among Polish surgical nurses in the light of anti-HBc prevalence: A cross-sectional sero-  
495 prevalence study. *Vaccine.* 2010;28: 3972–3976. doi:10.1016/j.vaccine.2010.03.042
- 496 29. Ansa GA, Ofori KNA, Houphouet EE, Amoabeng AA, Sifa JS, Amenuveve CK, et al.  
497 Hepatitis B vaccine uptake among healthcare workers in a referral hospital, Accra. *Pan Afr*  
498 *Med J.* 2019 Jun 10;33:96.
- 499 30. Senoo-Dogbey VE, Anto F, Quansah R, Danso-Appiah A. Completion of three-dose  
500 hepatitis B vaccination cycle and associated factors among health care workers in the  
501 Greater Accra Region of Ghana. *PloS One.* 2024;19(4):e0298771.
- 502 31. Issa A, Ayoola YA, Abdulkadir MB, Ibrahim RO, Oseni TIA, Abdullahi M, et al. Hepatitis  
503 B vaccination status among health workers in Nigeria: a nationwide survey between  
504 January to June 2021. *Arch Public Health.* 2023 Jul 4;81(1):123.
- 505 32. World Health Organization. Global health sector strategy on viral hepatitis 2016-2021.  
506 Towards ending viral hepatitis. World Health Organization; 2016.
- 507 33. Biset Ayalew M, Adugna Horsa B. Hepatitis B vaccination status among health care  
508 workers in a tertiary hospital in Ethiopia. *Hepatitis research and treatment.* 2017;2017.

- 509 34. Noubiap JJ, Nansseu JR, Kengne KK, Wonkam A, Wiysonge CS. Low hepatitis B vaccine  
510 uptake among surgical residents in Cameroon. *International archives of medicine*. 2014  
511 Dec;7(1):1-5.
- 512 35. Hussein NA, Ismail AM, Jama SS. Assessment of Hepatitis B Vaccination Status and  
513 Associated Factors among Healthcare Workers in Bosaso, Puntland, Somalia 2020.  
514 Komatsu H, editor. *BioMed Res Int*. 2022 Mar 21; 2022:1–7.
- 515 36. Abebaw TA, Aderaw Z, Gebremichael B. Hepatitis B virus vaccination status and  
516 associated factors among health care workers in Shashemene Zonal Town, Shashemene,  
517 Ethiopia: a cross sectional study. *BMC Res Notes*. 2017 Dec;10(1):260.
- 518 37. Ouédraogo HG, Kouanda S, Tiendrébeogo S, Konseimbo GA, Yetta CE, Tiendrébeogo E,  
519 Savadogo AA, Sondo B. Hepatitis B vaccination status and associated factors among health  
520 care workers in Burkina Faso. *Medecine et santé tropicales*. 2013 Jan 1;23(1):72-7.
- 521 38. Auta A, Adewuyi EO, Kureh GT, Onoviran N, Adeloye D. Hepatitis B vaccination  
522 coverage among health-care workers in Africa: A systematic review and meta-analysis.  
523 *Vaccine*. 2018 Aug;36(32):4851–60.
- 524 39. Ali AS, Hussein NA, Elmi EO, Ismail AM, Abdi MM. Hepatitis B vaccination coverage  
525 and associated factors among medical students: a cross-sectional study in Bosaso, Somalia,  
526 2021. *BMC Public Health*. 2023 Jun 3;23(1):1060.
- 527 40. Yuan Q, Wang F, Zheng H, Zhang G, Miao N, Sun X, et al. Hepatitis B vaccination  
528 coverage among health care workers in China. Chemin I, editor. *PLOS ONE*. 2019 May  
529 7;14(5):e0216598.

- 530 41. Guthmann JP, Fonteneau L, Ciotti C, Bouvet E, Pellissier G, Pellissier G, et al. Vaccination  
531 coverage of health care personnel working in health care facilities in France: results of a  
532 national survey, 2009. *Vaccine*. 2012; 30(31): 4648–54
- 533 42. Gyimah AA, Peprah P, Agyemang-Duah W, Frimpong E, Tsiboe AK, Darkwa MA.  
534 Hepatitis B vaccination status and associated factors among university students in Ghana:  
535 A cross-sectional survey. *Public Health and Primary Health Care*. 2021;8:e2005226.
- 536 43. Adekanle O, Komolafe AO, Olowookere SA, Ijarotimi O, Ndububa DA. Hepatitis B  
537 infection: a mixed methods of disclosure pattern and social problems in the Nigerian  
538 family. *Journal of Patient Experience*. 2020 Apr;7(2):208-16.
- 539 44. D. Ogoina, K. Pondei, B. Adetunji, G. Chima, C. Isichei, and S. Gidado, “Prevalence of  
540 hepatitis B vaccination among healthcare workers in Nigeria in 2011-12,” *The*  
541 *International Journal of Occupational and Environmental Medicine*, vol. 5, no. 1, pp. 51–  
542 56, 2014
- 543 45. Osei E, Niyilapah J, Kofi Amenuvegbe G. Hepatitis B knowledge, testing, and vaccination  
544 history among undergraduate public health students in Ghana. *BioMed research*  
545 *international*. 2019 Aug 14;2019.
- 546 46. Altamimi AR, Alqahtani TM, Ahmed JA, Aldosari LH, Alzahrani MM, Alotaibi GS,  
547 Moukaddem AK. Knowledge, awareness, and vaccination compliance of hepatitis B  
548 among medical students in Riyadh's governmental universities. *Journal of Family*  
549 *Medicine and Primary Care*. 2021 Jan 1;10(1):485-90.

550

551

